Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 2c,Condition 3a,Condition 3b,Condition 3c
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,144 days to 77 days,16,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,saline control group,,100,%,,,MMO:0000344,necropsy,,0.0,two treatment regimen,,,,DHD/K12/TRb cells (9 X 10E6) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days),111154,DHD/K12/TRb cells (9 X 10E6) ,splenectomy,0.9% sodium chloride solution (2 ml) (for 7 days),,,0.9% sodium chloride solution (2 ml) (for 7 days),,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,163 days to 77 days,18,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,fluorouracil 5-FU,,89,%,,,MMO:0000344,necropsy,,0.0,two treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days),111155,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),,,5-fluorouracil (100 mg/kg) (for 7 days),,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,164 days to 77 days,18,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,5-fluorouracil + interleukin-2,,22,%,,,MMO:0000344,necropsy,,0.0,two treatments,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days),111156,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days),,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days),
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,186 days to 77 days,21,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,5-fluorouracil + thymosin alpha-1 +interleukin-2,,9.5,%,,,MMO:0000344,necropsy,,0.0,two treatments,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days),111157,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days),5-fluorouracil (100 mg/kg) (for 7 days),thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days)
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,142 days to 77 days,13,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,saline control group,,100,%,,,MMO:0000344,necropsy,,0.0,,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days),111132,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,0.9% sodium chloride solution (2 ml) (for 7 days),,,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,146 days to 77 days,15,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,fluorouracil 5-FU,,93,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days),111133,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),,,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,141 days to 77 days,14,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,thymosin alpha-1,,100,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days),111134,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,thymosin alpha-1 (200 ug/kg) (for 4 days),,,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,146 days to 77 days,15,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,interleukin-2,,93,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days),111135,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,interleukin-2 (75000 U/d) (for 4 days),,,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,157 days to 77 days,15,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,5-fluorouracil + interleukin-2,,53,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days),111136,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days),,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,145 days to 77 days,15,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,5-fluorouracil + thymosin alpha-1,,87,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days),111137,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),thymosin alpha-1 (200 ug/kg) (for 4 days),,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,147 days to 77 days,14,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,thymosin alpha-1 + interleukin-2,,100,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days),111138,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days),,,,
3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",peritoneum integrity trait,,RS:0001792,BDIX/OrlCrl,male,162 days to 77 days,15,,CMO:0003785,percentage of study population developing extra-hepatic metastases during a period of time,,5-fluorouracil + thymosin alpha-1 +interleukin-2,,13,%,,,MMO:0000344,necropsy,,0.0,one treatment,,,,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days),111139,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,5-fluorouracil (100 mg/kg) (for 7 days),thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days),,,